Cystic Fibrosis Foundation Supports Development of Non-Porcine Enzyme Therapy

The Cystic Fibrosis Foundation has entered into an agreement with Synspira Therapeutics Inc. to develop a non-porcine enzyme replacement therapy to offer an alternative to people with cystic fibrosis who cannot digest food properly.

| 2 min read

Between 85 and 90 percent of people with CF are pancreatic insufficient. This occurs when thick, sticky pancreatic secretions block the release of enzymes needed to break down food for digestion. With no enzymes to break down food, much of the protein, fat and carbohydrate in food is not absorbed. This can result in poor growth, gastrointestinal symptoms like gas and bloating, and malnutrition.

To make up for this lack of enzymes, people with CF who are pancreatic insufficient should take pancreatic enzyme replacement therapy before they eat the majority of foods. Synspira's potential enzyme therapy SNSP003 contains three non-animal derived enzymes designed to break down fats, proteins, and carbohydrates (lipase, protease, and amylase, respectively).

Despite the approval of new treatments for the underlying cause of CF, many people with CF will continue to need treatments for complications such as malabsorption. The CF Foundation is dedicated to funding research into potential treatments for complications of CF, spending $62.5 million in 2018. There are more than 15 drugs in the pipeline, including potential anti-infectives, anti-inflammatories, mucociliary clearance therapies, and nutritional agents.

Share this article
Research | Our Research Approach
Recent news
CF Foundation Awards Advance Improvements in CF Newborn Screening
News | 4 min read
Cystic Fibrosis Foundation Awards 2023 Impact Grants
News | 5 min read
Adult with CF Provides Testimony at Congressional Hearing on the Impact of Antimicrobial Resistance 
News | 3 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.